Citizens Maintains Market Outperform on MiMedx Group, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 95.9%

Neg 95.9% Neu 0% Pos 0%

Citizens analyst David Turkaly maintains MiMedx Group (NASDAQ:MDXG) with a Market Outperform and lowers the price target from $10 to $7.